Katsuaki Maehara: Stage Ⅳ EGFRm NSCLC – Sequential Treatment Options

Katsuaki Maehara, Director of Medical Education Colleagues, recently shared the following on Twitter:

“Stage Ⅳ EGFRm NSCLC – Sequential Treatment Options

To organize sequential treatment, data are based on PFS.

We exclude acquired resistance to osimertinib (because the treatments differ).

2nd and 3rd line subsequent therapies cannot be fixed as they are determined by the IC of the Physician, patient/family, etc.”

Source: Katsuaki Maehara/Twitter